Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Anika Therapeutics Inc (NASDAQ:ANIK)

Delayed Data
As of Feb 05
 -0.48 / -1.26%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. The company's products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical and veterinary. The Orthobiologics products consist of joint health and orthopedic products which are used in a wide range of treatments from providing relief from the pain of osteoarthritis, to regenerating damaged tissue such as cartilage defects. The Dermal products consist of advanced wound care products and aesthetic dermal fillers which are used for the treatment of skin wounds ranging from burns to diabetic ulcers. The Ophthalmic business includes HA viscoelastic products used in ophthalmic surgery. The Surgical business consists of products used to prevent surgical adhesions and to treat ear, nose and throat disorders. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

Contact Information

Anika Therapeutics, Inc.
32 Wiggins Avenue
Bedford Massachusetts 01730
P:(781) 457-9000
Investor Relations:



Other institutional51.65%
Mutual fund holders34.19%
Individual stakeholders14.66%

Top Executives

Charles H. SherwoodPresident, Chief Executive Officer & Director
Francesco J. LuppinoChief Operating Officer
Sylvia CheungChief Financial Officer, Secretary & Treasurer
Edward S. AhnChief Technology & Strategy Officer
Edward GajVice President-Commercial Development